Objective: Insertion of DJ Stent is a procedure that is often done by urologist. Insertion of DJ Stent can cause LUTS complaints and greatly affect the physical and psychosocial health of patients. The aim of this study was to determine the effectiveness difference of tamsulosin therapy 0.4 mg/day, solifenacin 5 mg/day and the combination of tamsulosin therapy 0.4 mg/day added solifenacin 5 mg/day to manage LUTS complaint after DJ Stent insertion. Material & Methods: This study was a randomized placebo-controlled trial. There were 4 groups, group I received placebo, group II received tamsulosin 0.4 mg/day, group III received solifenacin 5 mg/day, and group IV received combination therapy of tamsulosin 0.4 mg/day added solifenacin 5 mg/day. Evaluation based on International Prostatic Symptom Score (IPSS) and Ureteral Stent Symptom Questioner (USSQ) score. Data were analyzed using SPSS 21.0. It is said to be significant if p<0.05. Results: There were a total of 32 samples consist of 19 (59.3%) men and 13 (40.6%) women. There were significant improvements in the score of total IPSS, IPSS storage and IPSS quality of life score in patients who received combination therapy (p<0.05) when compared with patients who received monotherapy. The highest decrease in USSQ scores 1, 2, 3, 4, 5 and 6 were in the group that received combination therapy when compared with the monotherapy group. Conclusion: The combination therapy is safe and effective to improve IPSS total, IPSS storage and IPSS Quality of Life scores compared with monotherapy.
Tamsulosin, solifenacin, combination therapy, double J stent, lower urinary tract symptoms.
Tailly T, Denstedt JD. Fundamentals of urinary tract. In: Kavoussi LR, Partin AW, Peters CA, Wein AJ. Campbell-Walsh Urology 11th ed. Philadelphia; Pa: Saunders Elsevier. 2016; 126-32.
Santosa SA, Rizaldi F, Soebadi DM. Pengaruh pemberian taldalafil dibandingkan dengan tamsulosin terhadap IPSS dan USSQ pada penderita pasca insersi double J stent. Unpublished Data; December 2016.
Subkhan, Budiono, Hakim L, Tarmono. Tamsulosin or solifenacin in LUTS patient due to DJ stent insertion. Indonesian Journal of Urology. July 2013; 20(2): 81-86.
Damiano R, Autorino R, De Sio M, Giacobbe A, Palumbo MI, D’Armiento M. Effect of tamsulosin in preventing ureteral stent-related morbidity: A Prospective Study. Journal of Endourology. 2008; 22(4): 651-6. PubMed PMID: 18338955.
Williams RC. Muscarinic receptor of urinary bladder: Detrusor, urothelial and prejunctional. Autonomic and Autacoid Pharmacology. 2012; 22: 133–45. PubMed PMID: 12452898.
Aggarwal SP, Priyadarshi S, Tomar V, Yadav SS, Gangkak G, Vyas N, et al. A randomized controlled trial to compare the safety and efficacy of tadalafil and tamsulosin in relieving double J stent related symptoms. Hindawi Publishing Corporation Advances in Urology. 2015: 1-6. PubMed Central PMCID: PMC4691600.
Navanitmitkul N, Lojanapiwat B. Efficacy of tamsulosin 0.4 mg/day in relieving double-J stent-related symptoms: A Randomize controlled study. The Journal of International Medical Research. 2010; 38: 1436–41. PubMed PMID: 20926016.
Abdelaal AM, Al-Adl A, Abdelbaki SH, AL Azab MM, Al Gamal KH. Efficacy and safety of tamsulosin oran-controlled absorption system, solifenacin and combined therapy for the management of ureteric stent-related symptoms. Arab Journal of Urology. 2016; 14: 115-22. PubMed PMID: 27489738.
Deliveliotis C, Chrisofos M, Gougousis E, Papatsoris A, Dellis A, Valkarakis M. Is there a role for alpha1-blockers in treating double-J stent-related symptoms?. The Journal of Urology. 2006; 67: 35–9. PubMed PMID: 16413328.
Taek Lim K, Tae Kim Y, Yong Lee T, Park SY. Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts. Korean Journal of Urology. 2011; 52: 485-8. PubMed PMID: 21860770.
Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX, Timoney AG. Indwelling ureteral stents: Evaluation of symptoms, quality of life and utility. Journal of Urology. 2003; 169: 1065-9. PubMed PMID: 12576847.
Rames RA, Horger DC. α-Adrenergic Antagonist in the treatment of benign prostatic hypertrophy – associated lower urinary tract symptoms. Management of Benign Prostatic Hypertrophy. Ner Jersey: Humana Press Inc. 2004; (5): 61-78.
Pavlo VA, Wang H, Czura CJ, Friedman SG. The cholinergic anti-inflammatory pathway: A missing link in neuroimmunomodulation. Molecular Medicine. 2009: 125-34. PubMed PMID:14571320.
Kuyumcuoglu U, Eryildirim B, Tuncer M, Faydaci G, Tarhan F, Ozg¨ul A. Effectiveness of medical treatment in overcoming the ureteral double-J stent related symptoms. Canadian Urological Association Journal. 2012; 6(6): E234–7. PubMed Central PMCID: PMC3529727.
Singh pawar D, Kumar D, Benjewal S, Mittal S, Lal J, Khandewal A, et al. Comparative study to evaluate effect of tamsulosin and solifenacin on DJ stent related symptoms. Journal of Dental and Medical Sciences. 2016; 15(10): 34-37.
Lee YJ, Huang KH, Yang HJ, Chang HC, Chen J, Yang TK. Solifenacin improves double-J stent-related symptomsin both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis. 2013; 41: 247–52. PubMed PMID: 23515684.
Shalaby E, Ahmed AF, Maarouf A, Yahia I, Ali M, Ghobbish A. Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-J stent-related lower urinary symptoms. Hindawi Publishing Corporation Advances in Urology. 2013: 1–7. PubMed PMID: 24235970.